FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2090786287> ?p ?o ?g. }

• W2090786287 endingPage "190" @default.
• W2090786287 startingPage "180" @default.
• W2090786287 abstract "The long-term efficacy and safety of formoterol dry powder capsules for inhalation in pediatric asthma have not previously been evaluated.We examined the effectiveness of inhaled formoterol over a period of 12 months in asthmatic children who were still symptomatic despite anti-inflammatory treatment.After a run-in period, 518 patients (5 to 12 years old) were randomized in a double-blind manner to receive 12 or 24 microg formoterol dry powder (Foradil, Novartis Pharma AG, Basel, Switzerland) or placebo twice daily for 12 months. The drug was administered by inhaler (Aerolizer, Novartis Pharma AG) and was given in addition to their anti-inflammatory treatment. The primary variable was the area under the curve for forced expiratory volume in 1 second measured over 12 hours after the morning dose of study medication.The area under the curve for forced expiratory volume in 1 second after the first dose of treatment and after 3 and 12 months of treatment was significantly greater for patients receiving formoterol 12 microg and 24 microg than for patients receiving placebo (all P < or = 0.0062). Compared with placebo, both doses of formoterol significantly improved morning and evening premedication peak expiratory flow rate (all P < 0.001). In the group treated with formoterol 24 microg, median symptom score and median dose of rescue medication at night were lower than during the run-in period, whereas the opposite occurred in the placebo group. The incidence of hospitalizations for asthma was higher in the formoterol groups than in the placebo group.Our results indicate that, in asthmatic children who are still symptomatic despite anti-inflammatory therapy, the addition of formoterol consistently improves airflow obstruction and nocturnal symptoms and reduces the use of rescue medication. However, this treatment requires close disease monitoring to detect early signs of acute exacerbation." @default.
• W2090786287 created "2016-06-24" @default.
• W2090786287 creator A5008677543 @default.
• W2090786287 creator A5019834570 @default.
• W2090786287 creator A5022249393 @default.
• W2090786287 creator A5022404377 @default.
• W2090786287 creator A5037087849 @default.
• W2090786287 creator A5037613564 @default.
• W2090786287 creator A5058523411 @default.
• W2090786287 creator A5078829922 @default.
• W2090786287 date "2002-08-01" @default.
• W2090786287 modified "2023-10-16" @default.
• W2090786287 title "One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma" @default.
• W2090786287 cites W1852853248 @default.
• W2090786287 cites W1932618311 @default.
• W2090786287 cites W1987062528 @default.
• W2090786287 cites W1995797675 @default.
• W2090786287 cites W2000522781 @default.
• W2090786287 cites W2021302369 @default.
• W2090786287 cites W2053471558 @default.
• W2090786287 cites W2064651388 @default.
• W2090786287 cites W2064766457 @default.
• W2090786287 cites W2066209909 @default.
• W2090786287 cites W2070079663 @default.
• W2090786287 cites W2079645048 @default.
• W2090786287 cites W2079650976 @default.
• W2090786287 cites W2088520852 @default.
• W2090786287 cites W2096598461 @default.
• W2090786287 cites W2098633046 @default.
• W2090786287 cites W2107458343 @default.
• W2090786287 cites W2123309257 @default.
• W2090786287 cites W2126441272 @default.
• W2090786287 cites W2155817164 @default.
• W2090786287 cites W2168316735 @default.
• W2090786287 cites W2319554819 @default.
• W2090786287 cites W2331287401 @default.
• W2090786287 cites W4236639597 @default.
• W2090786287 doi "https://doi.org/10.1016/s1081-1206(10)61935-7" @default.
• W2090786287 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12197575" @default.
• W2090786287 hasPublicationYear "2002" @default.
• W2090786287 type Work @default.
• W2090786287 sameAs 2090786287 @default.
• W2090786287 citedByCount "76" @default.
• W2090786287 countsByYear W20907862872012 @default.
• W2090786287 countsByYear W20907862872013 @default.
• W2090786287 countsByYear W20907862872014 @default.
• W2090786287 countsByYear W20907862872016 @default.
• W2090786287 countsByYear W20907862872018 @default.
• W2090786287 countsByYear W20907862872019 @default.
• W2090786287 countsByYear W20907862872022 @default.
• W2090786287 crossrefType "journal-article" @default.
• W2090786287 hasAuthorship W2090786287A5008677543 @default.
• W2090786287 hasAuthorship W2090786287A5019834570 @default.
• W2090786287 hasAuthorship W2090786287A5022249393 @default.
• W2090786287 hasAuthorship W2090786287A5022404377 @default.
• W2090786287 hasAuthorship W2090786287A5037087849 @default.
• W2090786287 hasAuthorship W2090786287A5037613564 @default.
• W2090786287 hasAuthorship W2090786287A5058523411 @default.
• W2090786287 hasAuthorship W2090786287A5078829922 @default.
• W2090786287 hasConcept C121332964 @default.
• W2090786287 hasConcept C126322002 @default.
• W2090786287 hasConcept C1276947 @default.
• W2090786287 hasConcept C142724271 @default.
• W2090786287 hasConcept C19720800 @default.
• W2090786287 hasConcept C204787440 @default.
• W2090786287 hasConcept C27081682 @default.
• W2090786287 hasConcept C2776042228 @default.
• W2090786287 hasConcept C2776136866 @default.
• W2090786287 hasConcept C2776476923 @default.
• W2090786287 hasConcept C2776954882 @default.
• W2090786287 hasConcept C2777419714 @default.
• W2090786287 hasConcept C2779871671 @default.
• W2090786287 hasConcept C2780261241 @default.
• W2090786287 hasConcept C2781018748 @default.
• W2090786287 hasConcept C2909086917 @default.
• W2090786287 hasConcept C42219234 @default.
• W2090786287 hasConcept C71924100 @default.
• W2090786287 hasConceptScore W2090786287C121332964 @default.
• W2090786287 hasConceptScore W2090786287C126322002 @default.
• W2090786287 hasConceptScore W2090786287C1276947 @default.
• W2090786287 hasConceptScore W2090786287C142724271 @default.
• W2090786287 hasConceptScore W2090786287C19720800 @default.
• W2090786287 hasConceptScore W2090786287C204787440 @default.
• W2090786287 hasConceptScore W2090786287C27081682 @default.
• W2090786287 hasConceptScore W2090786287C2776042228 @default.
• W2090786287 hasConceptScore W2090786287C2776136866 @default.
• W2090786287 hasConceptScore W2090786287C2776476923 @default.
• W2090786287 hasConceptScore W2090786287C2776954882 @default.
• W2090786287 hasConceptScore W2090786287C2777419714 @default.
• W2090786287 hasConceptScore W2090786287C2779871671 @default.
• W2090786287 hasConceptScore W2090786287C2780261241 @default.
• W2090786287 hasConceptScore W2090786287C2781018748 @default.
• W2090786287 hasConceptScore W2090786287C2909086917 @default.
• W2090786287 hasConceptScore W2090786287C42219234 @default.
• W2090786287 hasConceptScore W2090786287C71924100 @default.
• W2090786287 hasIssue "2" @default.
• W2090786287 hasLocation W20907862871 @default.
• W2090786287 hasLocation W20907862872 @default.

• next